SCHEMBL675985

SCHEMBL675985

COc1cccc2c1C(OC)OC2=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.62
AR P10275 1/20 0.43
ACHE P22303 1/20 0.42
TOP1 P11387 1/20 0.42
NUAK1 O60285 1/20 0.41
IGF1R P08069 1/20 0.41
MET P08581 1/20 0.41
SRC P12931 1/20 0.41
AXL P30530 1/20 0.41
KDR P35968 1/20 0.41
NEK2 P51955 1/20 0.41
PTK2 Q05397 1/20 0.41
AURKB Q96GD4 1/20 0.41
ALK Q9UM73 1/20 0.41
NQO1 P15559 1/20 0.40
POR P16435 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5421944 0.81 KDM4E (0.47) KDM4EARNUAK1IGF1RMET
SCHEMBL11474768 0.80 KDM4E (0.55) KDM4EARACHELMNAALDH1A1
SCHEMBL87129 0.79 ACHE (0.43) KDM4EACHETOP1NQO1POR
SCHEMBL20552496 0.79 AR (0.44) KDM4EARACHETOP1NQO1
SCHEMBL11394821 0.79 NQO1 (0.43) KDM4EACHETOP1NQO1POR
SCHEMBL3901331 0.79 AR (0.44) KDM4EARACHETOP1NQO1
SCHEMBL28568179 0.77 KDM4E (1.00) KDM4EARMEN1KMT2ALMNA
SCHEMBL5421727 0.74 S100A4 (0.44) KDM4ENUAK1IGF1RMETSRC
SCHEMBL10495516 0.74 AKT1 (0.48) KDM4EACHETOP1NQO1POR
SCHEMBL17501668 0.73 NR3C1 (0.42) ARACHELMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109055233-B Fungus for producing dimethoxy isobenzofuran-1-one and method for preparing dimethoxy isobenzofuran-1-one by fungus 黑龙江大学 2021-08-17 CN claimed
US-20110274651-A1 Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition EMORY UNIVERSITY (US) 2011-11-10 US disclosed
EP-2328578-A2 NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION Emory University (US) 2011-06-08 EP disclosed
WO-2010030582-A2 NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION EMORY UNIVERSITY (US) 2010-03-18 WO disclosed
CN-1284070-A Alicyclic acylated heterocyclic derivatives SANKYO CO (JP) 2001-02-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110274651-A1 Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition NOS1, NOS2, TBCA KDM4E 4136/4885AR 4510/4885ACHE 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.